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Background: Counterfeit and unapproved medicines are inherently dangerous and can cause patient injury due to
ineffectiveness, chemical or biological contamination, or wrong dosage. Growth of the counterfeit medical market in
developed countries is mainly attributable to life-style drugs, which are used in the treatment of non-life-threatening and
non-painful conditions, such as slimming pills, cosmetic-related pharmaceuticals, and drugs for sexual enhancement. One
of the main tasks of health authorities is to identify the exact active pharmaceutical ingredients (APIs) in confiscated drugs,
because wrong API compounds, wrong concentrations, and/or the presence of chemical contaminants are the main risks
associated with counterfeit medicines. Serious danger may also arise from microbiological contamination. We therefore
performed a market surveillance study focused on the microbial burden in counterfeit and unapproved medicines.
Methods: Counterfeit and unapproved medicines confiscated in Canada and Austria and controls from the legal market
were examined for microbial contaminations according to the US and European pharmacopoeia guidelines. The
microbiological load of illegal and legitimate samples was statistically compared with the Wilcoxon rank-sum test.
Results: Microbial cultivable contaminations in counterfeit and unapproved phosphodiesterase type 5 inhibitors were
significantly higher than in products from the legal medicines market (p < 0.0001). Contamination levels exceeding the
USP and EP limits were seen in 23% of the tested illegal samples in Canada. Additionally, microbiological contaminations
above the pharmacopoeial limits were detected in an anabolic steroid and an herbal medicinal product in Austria (6% of
illegal products tested).
Conclusions: Our results show that counterfeit and unapproved pharmaceuticals are not manufactured under the same
hygienic conditions as legitimate products. The microbiological contamination of illegal medicinal products often exceeds
USP and EP limits, representing a potential threat to consumer health.Background
The counterfeiting of pharmaceuticals has been a known
problem for decades. In recent years, the challenge has es-
calated and the numbers of counterfeit drugs have in-
creased continuously, not only in developing but also in
developed countries [1]. Available estimates on the value
of the global market for counterfeit drugs are in the range
of US$ 75 to US$ 200 billion, indicating the significance of
the problem [1,2]. In West Africa alone, the illegal anti-
malarial drug market may exceed US$ 400 million [3,4]. In
developed countries, life-style drugs, such as phospho-
diesterase type 5 (PDE5) inhibitors used for the treatment* Correspondence: Dieter.Pullirsch@ages.at; Jacques.Gagnon@hc-sc.gc.ca
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reproduction in any medium, provided the orof erectile dysfunction, seem to be the main targets for
counterfeiting [5]. In the face of rising drug costs, counter-
feit versions of cancer drugs and other life-saving medicines
are also on the rise worldwide [6]. Overall, any medication
that is in high demand is an attractive target for counter-
feiters [5].
According to the definition by the World Health
Organization (WHO), a counterfeit medicine is “one which
is deliberately and fraudulently mislabelled with respect to
identity and/or source. Counterfeiting can apply to both
branded and generic products and counterfeit products
may include products with the correct ingredients or with
the wrong ingredients, without active ingredients, with in-
sufficient active ingredients or with fake packaging” [7].
However, “a counterfeit drug is defined differently in differ-
ent countries” [7].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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out having been granted a marketing authorisation by
health authorities [8]. Unapproved drugs are often mar-
keted as being similar to, or a foreign version of, an ap-
proved drug. Such medicines may indeed comply with the
quality standards in their country of origin, but because
they are not imported or sold through the legal supply
chain, their origin often remains unclear and their compli-
ance with the quality standards of the target country can-
not be verified [9,10].
Consumers are generally unaware of the dangers asso-
ciated with the use of counterfeit and unapproved life-
style drugs. Next to treatments for erectile dysfunction,
appearance-enhancing medications such as slimming
pills or anabolic steroids are in high demand. While
non-treatment with these drugs does not lead to detri-
mental health effects, their use can result in dangerous
adverse effects caused by overdosed content or contam-
inations [6]. Additionally, consumers of life-style drugs
often bypass the healthcare system, so that underlying
diseases, such as coronary artery disease, obesity, or an-
orexia, cannot be detected and pharmacodynamic or
pharmacokinetic interactions with other drugs or sub-
stances cannot be identified and prevented [5].
Security and encryption experts are continuously working
to devise new methods to protect originator drugs from be-
ing counterfeited. Thus, secret colour compositions and
packaging materials as well as holograms interpretable only
with laser readers have been developed to prevent counter-
feits from entering the legal supply chain [11]. Yet, counter-
feit drugs in developed countries are mainly detected on
the illegal pharmaceutical market. Consumers buy medica-
tions via the internet to save money or time or because they
are too embarrassed about their health problems to seek
professional help [5]. The WHO estimates that 50% of
medicines bought from online pharmacies that do not list
their physical address are counterfeits [12].
The pharmacological content of counterfeit medicines
has been examined by both authorities and manufacturers
of original products [5]. For example, with PDE5 inhibi-
tors being a main target for counterfeiting, they have been
extensively studied [13,14]. A serious incident with coun-
terfeit PDE5 inhibitors occurred in Singapore in 2008,
when 4 people died due to hypoglycaemia caused by coun-
terfeits contaminated with glyburide [15].
Microbial contamination and infection are known to be
serious risks associated with illegal drug use, the legal use of
pharmaceuticals distributed under poor hygienic conditions,
and counterfeit medicines for parenteral administration
[16-18]. For example, according to a recently published re-
port from Shanghai, China, intravitreal injection of counter-
feit bevacizumab contaminated with endotoxin caused acute
intraocular inflammation in a series of 80 patients, 21 of
whom had to undergo vitrectomy as a result [19]. Whereasparenteral pharmaceuticals must be sterile, non-sterile
products may be administered to regions of the human
body that are rich in microbial flora and have physical
or immunological barriers to infection [20]. However,
the US and European pharmacopoeiae state that even in
non-sterile preparations, the presence of certain micro-
organisms “may have the potential to reduce or even in-
activate the therapeutic activity of the product and has a
potential to adversely affect the health of the patient.
Manufacturers therefore have to ensure a low biobur-
den of finished dosage forms by implementing current
guidelines on Good Manufacturing Practice during the
manufacture, storage and distribution of pharmaceutical
preparations” [21,22]. Microbiological contamination
levels above pharmacopoeial limits may lead to alter-
ations and spoilage of active ingredients and cause ad-
verse effects by infections or toxins.
We here present the results from marketing surveillance
studies performed by the Canadian and Austrian official
control laboratories between 2008 and 2011 on microbio-
logical contaminations in illegal medicines. Because mi-
crobial contamination is a well-known and already widely
documented threat for sterile parenteral medicines and
because counterfeit and unapproved drugs are frequently
sold as solid dosage forms, the main focus of our studies
was on solid life-style drugs.
Methods
All experiments were performed by Health Canada and
by the AGES Austrian Medicines and Medical Devices
Agency. Both organizations are responsible for market
surveillance in their respective countries.
Canadian study design
Health Canada defines a counterfeit health product as one
that is represented as, and likely to be mistaken for, an au-
thentic product [23]. Analyses focused on randomly se-
lected counterfeit and unapproved drugs for the treatment
of erectile dysfunction from the illegal market. Twenty-
one counterfeit and 31 unapproved PDE5 inhibitors were
analysed for microbial contamination. As controls, sam-
ples of all available PDE5 inhibitors were obtained from
the legal market (Viagra® 25, 50, 100 mg; Cialis® 2.5, 5, 10,
20 mg; Levitra® 5, 10, 20 mg) and analysed. All counterfeit
and unapproved samples had been seized by the Royal
Canadian Mounted Police or Border Integrity Officers be-
tween 2008 and 2010.
The drugs were tested for compliance with the US
Pharmacopoeia. A total of five microbiological analyses
were performed on the samples: total aerobic microbial
count (TAMC), total yeast and mould count (TYMC),
pathogens (Escherichia coli, Pseudomonas aeroginosa,
Salmonella, and Staphylococcus aureus), and enumer-
ation of enterobacteriae and anaerobic bacteria. All
Table 1 Microbiological contamination in counterfeit and








Sildenafil 50 mg < 5 < 5 nd
Tadalafil 10 mg < 5 < 5 nd
Vardenafil 10 mg < 5 < 5 nd
Counterfeit PDE5 inhibitors
Sildenafil 100 mg #1 < 5 < 5 nd
Sildenafil 100 mg #2 < 5 10 negative
Sildenafil 100 mg #3 < 5 < 5 nd
Sildenafil 100 mg #4 < 5 < 5 nd
Sildenafil 100 mg #5 < 5 < 5 nd
Sildenafil 100 mg #6 170 < 5 negative
Tadalafil 80 mg #7 < 5 < 5 nd
Other unapproved products
Zinc gluconate #8 < 5 < 5 nd
Nicotic acid #9 < 5 < 5 nd
Methandienone #10 80 < 5 negative
Methandienone #11 11 000 < 5 negative
Mephedrone HCl #12 n/a n/a n/a
Butylone HCl #13 n/a n/a n/a
Methandienone #14 80 60 negative
Stanozolol #15 100 < 5 negative
Stanozolol #16 110 < 5 negative
Clenbuterole 0.02 mg #17 < 5 < 5 nd
Sibutramine, phenolphtalein #18 20 40 negative
Sildenafil 100 mg #19 < 5 < 5 nd
4-Methylethcathinone #20 < 5 < 5 nd
4-Methylcathinone/Coffein #21 < 5 < 5 n/a
4-Methylcathinone/Coffein #22 < 5 < 5 n/a
4-Methylcathinone/Coffein #23 < 5 < 5 nd
3-Fluoromethcathinone/
Lidocaine/Coffein #24
< 5 < 5 nd
Coffein/Acetylsalicylic acid #25 < 5 < 5 nd
Slimming herb #26
(herbal product)
720 000 4 000 >104 bile-tolerant
gram-negative
bacteria
TAMC: Total aerobic microbial count; TYMC: Total yeast and mould count; nd:
Not determined; n/a: Not applicable (interfering substance prevented
successful completion of the test).
Illegal medicines confiscated in Austria were analysed for microbiological
contaminations by microbial enumeration tests and tests for specific pathogens.
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culture media, were conducted in accordance with the US
Pharmacopoeia (USP), Chapters 61 and 62 [24,25], which
are harmonized with the European Pharmacopoeia (EP).
The assay for sildenafil citrate content was performed ac-
cording to the corresponding USP monograph.
Austrian study design
According to the European Medicines Agency, counterfeit
medicines are medicines that fail to comply with intellectual-
property rights or infringe trademark law [26].
Seven counterfeit PDE5 inhibitors and 26 unapproved
medicines (25 solid dosage forms and 1 herbal tea) from
the illegal market were randomly selected and analysed for
microbial contamination. Unapproved medicines consisted
of suspected performance-enhancing drugs or slimming
agents (Table 1). As a reference, PDE5 inhibitor products
(Viagra® 50 mg; Cialis® 10 mg; Levitra® 10 mg) were ob-
tained from the legal market and examined for microbial
contaminations. The drugs had been seized by the Austrian
police and the Austrian customs agency between 2008 and
2011. All samples were tested for EP compliance. As in the
Canadian study, analyses for TAMC, TYMC, pathogens
(Escherichia coli, Pseudomonas aeroginosa, Salmonella and
Staphylococcus aureus), enterobacteriae, and anaerobic bac-
teria were performed as applicable. All analyses, including
handling procedures, dilutions and culture media, were
conducted in accordance with the EP, Chapters 2.6.12,
2.6.13, and 2.6.31 [27-29], which are harmonized with the
USP. The assay for sildenafil citrate content was performed
according to the corresponding EP monograph.
Acceptance criteria in the USP and EP
According to the USP and EP, the acceptance criteria for
non-aqueous preparations for oral use are 103 colony-
forming units (CFU)/g in the TAMC test and 102 CFU/g
in the TYMC test. The acceptance criterion for herbal
products with cold extraction is 105 CFU/g in the TAMC
test, 104 in the TYMC test, and 104 for bile-tolerant gram-
negative bacteria.
According to the USP and EP, the acceptance criteria of
103 CFU/g were interpreted as a maximum acceptable
count of 2000 CFU/g. The acceptance criterion of 105
CFU/g for herbal products with cold extraction was inter-
preted as a maximum acceptable count of 500 000 CFU/g.
Statistical analysis
Due to the skewed distribution of microbiological burden,
the non-parametric Wilcoxon rank-sum test, applying the
normal approximation, was used to test for differences be-
tween medicines in the degree of microbiological contam-
ination. In addition, Fisher’s exact test was used to
compare contamination after dichotomization, both with
respect to no/any microbiological burden as well aswith respect to the acceptance limit of < = 2000 CFU/g
versus >2000 CFU/g as defined according to the USP
and EP. All statistical tests are presented with two-sided
significance levels. The Wilcoxon rank-sum test compar-
ing microbiological contamination of legal versus illegal
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the primary analysis.
Results
Only counterfeit and unapproved PDE inhibitors showed
increased contamination
Not a single CFU was detected in the approved PDE5 in-
hibitor products obtained through the legal pharmaceut-
ical supply chain—neither in the Canadian nor in the
Austrian study. Thus, although the USP and EP allow an
upper limit of 103 CFU/g, no cultivable microbial contam-
inations were detected for these pharmaceuticals produced
under controlled GMP conditions (Figure 1).
In the Canadian study, 12 of the 31 unapproved PDE5
inhibitor samples (39%) were contaminated with more
than 103 CFU/g (Figure 1). Taking counterfeit and un-
approved drugs together, 12 of the 52 samples (23%)
were contaminated with more than 103 CFU/g, 36 sam-
ples (69%) showed increased levels of microbial contam-
ination that were within the acceptable limits, and only
4 of the 52 illegal products (8%) showed excellent results
with no cultivable contamination.
In the Austrian study, none of the 7 counterfeit PDE5
inhibitor samples tested showed a microbial contamin-
ation above the EP limit. Contamination with colony-
forming microorganisms within EP limits was found in 2
of the 7 samples (29%, Table 1).
Statistical analysis of increased microbiological burden in
counterfeit and unapproved PDE5 inhibitors in Canada
Wilcoxon rank-sum and Fisher’s exact tests were performed
to test for statistical significance of observed differences be-
tween legal and illegal (counterfeit and unapproved) PDE5Figure 1 Microbiological load in PDE5 inhibitors in Canada. Products f
drugs were tested for microbiological contamination. The pharmacopoeialinhibitors in Canada. In the Wilcoxon rank-sum test, the
degree of microbiological contamination (CFU/g) in illegal
medicines was significantly higher than in the legal products
(p < 0.0001, two-sided). The Fisher’s exact test demonstrated
that the number of contaminated illegal samples (>0 CFU/g;
as opposed to no contamination at all) was statistically sig-
nificantly higher than in legal samples (p < 0.0001, two-
sided). Overall, therefore, both the number of cultivable
contaminations (Wilcoxon rank-sum test) and the number
of contaminated samples (>0 CFU/g; Fisher’s exact test)
were significantly higher among illegal PDE5 inhibitors.
Comparison for non-compliance with the pharmacopoeia
limits (>2000 CFU/g) did not show a statistically significant
difference between illegal and legal medicines, but a clear
trend was observed (p = 0.1864, two-sided Fisher’s exact test).
Unapproved medicines showed a clear statistically significant
increase of non-compliance when compared to the counter-
feit products (p < 0.0001, two-sided Fisher’s exact test).
Due to the limited number of PDE5 inhibitors from
Austria, statistical analysis was only performed for the
Canadian market.
Bacillus contaminations were frequent in counterfeit and
unapproved PDE5 inhibitors
The identified species are summarized in Table 2.
None of the pathogens specifically defined in the phar-
macopeiae were detected. Amongst others, mainly
contaminations with Bacillus ssp. were observed. Iden-
tified Bacillus species included B. firmus, B. lentus, B.
megaterium, B. pumilus, B. polymyxa, B. subtillis/amy-
loliquefaciens/atrophaeus, B. licheniformis, B. cereus/thur-
ingensis/mycoides, B. pumilus, B. coagulans, B. fusiformis,
B. circulans, and B. glucanolyticus.rom the legal market (black), counterfeit (blue), and unapproved (red)
limits of 103 CFU (2000 counts)/g are indicated by the green line.
Table 2 Identified bacterial species in counterfeit and
illegal PDE inhibitors in the Canadian study
Product Identified bacteria
Approved PDE5 inhibitors
Sildenafil 25 mg n/a
Sildenafil 50 mg n/a
Sildenafil 100 mg n/a
Tadalafil 2.5 mg n/a
Tadalafil 5 mg n/a
Tadalafil 10 mg n/a
Tadalafil 20 mg n/a
Vardenafil 5 mg n/a
Vardenafil 10 mg n/a
Vardenafil 20 mg n/a
Counterfeit PDE5 inhibitors
Sildenafil 100 mg #1 Bacillus spp.
Sildenafil 100 mg #2 Serratia spp., Paenibacillus polymyxa, Paenibacillus
amylolyticus, Bacillus ssp., Paenibacillus gluconolyticus,
Corynebacterium spp., Brevibacillus borstelensis
Sildenafil 100 mg #3 Brevibacillus choshinensys, Bacillus spp.
Sildenafil 100 mg #4 Bacillus ssp.
Sildenafil 100 mg #5 Bacillus spp.




acnes, Brevibacillus borstelensis, Bacillus spp.
Sildenafil 100 mg #7 Micrococcus luteus
Sildenafil 100 mg #8 Bacillus ssp., Propionibacterium acnes
Sildenafil 100 mg #9 Paenibacillus amylolyticus
Sildenafil 100 mg #10 Brevibacillus choshinensys
Sildenafil 100 mg #11 n/a
Sildenafil 100 mg #12 n/a
Tadalafil 20 mg #13 Bacillus ssp.
Tadalafil 20 mg #14 Kocuria rosea, Bacillus pumilus
Tadalafil 10 mg #15 Bacillus spp
Tadalafil 10 mg #16 Bacillus spp
Tadalafil 10 mg #17 Granulicatella adiacens, Streptococcus
salivarus, Bacillus spp
Tadalafil 10 mg #18 Bacillus spp
Tadalafil 10 mg #19 Bacillus spp
Vardenafil 20 mg #20 Bacillus spp
Vardenafil 20 mg #21 n/a
Unapproved PDE5 inhibitors
Tadalafil #22 Paenibacillus lautus, Paenibacillus durus,
Paenibacillus glucanolyticus, Bacillus spp.
Sildenafil #23 Bacillus ssp., Paenibacillus spp.
Vardenafil #24 Bacillus ssp.
Tadalafil #25 Staphylococcus epidermidis, Bacillus spp.
Table 2 Identified bacterial species in counterfeit and
illegal PDE inhibitors in the Canadian study (Continued)
PDE5 inhibitor #26 Bacillus spp.,
Tadalafil #27 Bacillus spp.
Sildenafil #28 Bacillus spp.
Sildenafil #29 Bacillus spp.
Sildenafil #30 Bacillus spp., Sphingomonas paucimobilis,
aerobic Actinomycetes
Sildenafil #31 Bacillus spp.
Tadalafil #32 Bacillus spp.
Tadalafil #33 Bacillus spp.
Tadalafil #34 Granulicatella adiacens,
Streptococcus salivarus, Bacillus spp.
Sildenafil #35 Bacillus spp.
Sildenafil #36 Bacillus spp., Micrococcus spp.
Sildenafil #37 Bacillus spp.
Sildenafil #38 Bacillus spp.
Sildenafil #39 Bacillus spp.
Tadafenil #40 Bacillus spp.
Sildenafil #41 Bacillus spp.
Sildenafil #42 Bacillus spp.
Tadafenil #43 Bacillus spp., Staphylococcus hominis
Sildenafil #44 Bacillus spp.
Sildenafil #45 Bacillus spp.
Sildenafil #46 Bacillus spp.
Sildenafil #47 Bacillus spp.
Sildenafil #48 Bacillus spp.
Sildenafil #49 Bacillus spp.
Sildenafil #50 Bacillus spp.
Sildenafil #51 Bacillus spp.
Sildenafil #52 Bacillus spp.
n/a: Not applicable.
Bacterial species identified in the contaminated samples of Figure 1.
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counterfeit PDE5 inhibitors
Although this was not the main focus of our study, we also
examined the content of active ingredients in the counter-
feit samples (Additional file 1). Of all 26 counterfeits tested,
24 (92%) did not contain the labelled amount of PDE5 in-
hibitor (acceptance criterion ± 10% of the labelled amount).
In 21 samples (81%), a reduced content of the active ingre-
dient was detected, whereas 3 samples (12%) were about 2-
fold over-dosed. Interestingly, 14 of the 26 samples (54%)
also contained trace amounts of a second PDE5 inhibitor.
Microbiological contamination in other product
classes tested
When examining the 25 non-PDE5-inhibitor unapproved
medicines with solid dosage forms from the Austrian
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taminated with 1.1 × 104 CFU/g in the TAMC test, thus
exceeding the EP limit of 103 CFU/g. Of the 25 un-
approved medicines, one (4%) did not comply with EP
standards and an additional 7 (28%) showed a microbial
load higher than that seen in the legal products manufac-
tured under defined GMP conditions.
Increased microbiological burden in an unapproved
herbal product
One unapproved herbal medicinal product was tested in
Austria. The product contained brown-coloured dried
plant tissue and was contaminated with 720 000 CFU/g in
the TAMC test (Table 1), exceeding the acceptance criter-
ion of 105 CFU/g (maximum of 500 000 counts). Besides,
the sample also exceeded the EP limit of 104 CFU/g of
bile-tolerant gram-negative bacteria. Klebsiella pneumonia
was identified as the prevalent bile-tolerant species.
Discussion
The microbiological content in non-sterile products has to
be controlled to a level consistent with patient safety [20].
Microbial enumeration tests are required to demonstrate
production under acceptable hygienic conditions. When-
ever pharmacopoeial limits are exceeded, the microbio-
logical quality of manufacturing was not sufficiently
controlled and adverse effects on product and patient
safety cannot be excluded. Additionally, according to the
US and European pharmacopoeiae, the significance of re-
covered microorganisms must be evaluated and the ab-
sence of specific pathogens demonstrated depending on
the route of administration [21,22]. Microbiological con-
taminations may be introduced by the raw material,
through the manufacturing process, or during packaging
and transport, and risk-based control points should be in-
corporated into the manufacturing process [20].
Our data, derived from independent studies performed in
two different pharmaceutical markets, confirm that coun-
terfeit and unapproved medicines are not manufactured
under the same hygienic condition as genuine products.
The Canadian and Austrian studies presented both showed
that none of the PDE5 inhibitors from the legitimate supply
chain produced under GMP conditions contained any mi-
crobial burden detectable by routine pharmacopoeial test-
ing, whereas 92% of Canadian and 29% of Austrian PDE5
inhibitor samples seized from the illegal market contained
cultivable contaminations. Also, 23% of counterfeit and un-
approved PDE5 inhibitors seized in Canada and 6% of all
tested samples from the Austria illegal market failed to
comply with the pharmacopoeial limits in microbial enu-
meration tests.
In the Canadian study, the microbiological contamina-
tions in unapproved products were higher than in coun-
terfeit products. It may be hypothesized that individualsproducing counterfeit products may be more intent on
using reasonably safe production conditions than those
trading in unapproved products. However, the difference
between counterfeit and unapproved products seen in our
study may not be generalizable. Thus, we found that both
product groups contained higher amounts of microbio-
logical contaminations than products from the legal mar-
ket, indicating that both groups may be expected to be
prepared under less hygienic production conditions than
genuine medicinal products. In the Austrian study, a
higher rate of contaminations above EP limits was also ob-
served for unapproved than in counterfeit products, but
due to the different nature of the products tested in
Austria, direct statistical comparison was not performed.
Most identified contaminating bacteria in PDE5 inhibi-
tors belong to the Bacillus genus. Bacillus ssp. can form
resistant endospores and are part of the normal environ-
mental flora [30]. This may be indicative of contamination
by human manipulators. Although no major pathogens were
isolated, some of the identified Bacillus species are capable of
causing human infection [30]. Besides, Serratia species, Pro-
pionibacterium acnes, Granulicatella adiacens, Streptococcus
salivarus, Staphylococcus epidermidis, Staphylococcus homi-
nis, Enterococcus gallinarum, and Sphingomonas paucimobi-
lis were identified and have the potential to cause clinical
symptoms of infection [31,32]. In view of the oral route
of administration of PDE5 inhibitors, the bacterial spe-
cies detected may not pose an increased risk to con-
sumers, provided that the total counts do not exceed
pharmacopoeial limits.
Klebsiella pneumoniae was identified in an unapproved
herbal medicinal tea, with the included package leaflet
recommending extraction with cold water. This method
of extraction may not be expected to reduce viable con-
taminations. K. pneumoniae is a gram-negative bacterium
that can cause bacterial pneumonia and hospital-acquired
urinary tract and wound infections [33]. K. pneumoniae
mainly attacks immunocompromised patients and individ-
uals with underlying diseases, such as diabetes mellitus
[33]. The examined infusion failed to comply with the EP
limits for bile-tolerant gram-negative bacteria and for total
bacterial counts (TAMC). Although the concentrations of
K. pneumoniae detected in this product are unlikely to
lead to clinical infection in healthy humans [34], a poten-
tial threat cannot be excluded, especially when storage
conditions are not monitored and further bacterial growth
might occur.
Two potential threats arise from microbiological contam-
inations in pharmaceutical products. First, certain microor-
ganisms may alter the quality of the active ingredients and
even lead to spoilage of the product. Second, microbio-
logical contaminations may directly cause adverse effects by
producing toxins or causing infections. Product alterations
are less likely in solid PDE5 inhibitors but may occur in
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logical contaminations are higher for herbal products and
products with a moisture content that supports bacterial
survival and growth than for solid dosage forms. Accord-
ingly, a recent study found high levels of bacterial contami-
nations in counterfeit toothpaste [35], and an outbreak of
Salmonella montevideo has been associated with a dietary
herbal food supplement [36]. Herbal products show higher
levels and limits of contamination because of the raw mate-
rials they contain and the mild production methods used.
In contrast, PDE5 inhibitors are less likely to be contami-
nated with bacteria due to the synthetisation process of the
active substances, the chemicals used, and the low moisture
content. Even in synthesised medicines, however, contami-
nations by excipients or cutting agents and human manipu-
lation during manufacture and transport pose a risk when
hygienic production conditions are not guaranteed. In re-
cent years, several cases of injectional anthrax most likely
caused by contaminated heroin have been described in
Europe [37]. Suggested routes of contaminations included
animal-derived sources, such as bone meal or animal hides
[38]. Although this is clearly a worst-case scenario associ-
ated with injectional administration of an illicit drug, it il-
lustrates that the lack of controls during manufacturing
and/or transport of pharmaceutical active substances can
lead to contamination with severe pathogens. Interestingly,
despite good evidence for the cause of infection, neither
B. anthracis nor its genome was detected in any of the her-
oin samples tested [37]. The production of illegal drugs and
illegal pharmaceuticals might differ, but for both, in the
absence of strictly quality-controlled hygienic production
conditions, even testing for specific pathogens may not be
sufficient to detect serious contaminations.
Conclusions
Based on our studies, it may be assumed that various
groups of illegal medications contain increased levels of
microbial contaminations. Our results demonstrate that il-
legal pharmaceuticals are produced under less hygienic
conditions than legitimate products manufactured under
controlled and defined GMP conditions.
To gain broader insights into the microbiological bur-
den in counterfeit drugs, we recommend the risk-based
inclusion of microbiological quality studies in the sur-
veillance of the illegal pharmaceutical market.Additional file
Additional file 1: PDE5 inhibitor content in counterfeit drugs from
Canada and Austria. Inconsistent doses of active pharmaceutical
ingredients were detected in counterfeit PD5 inhibitors.Competing interests
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